Is It Too Late To Reassess Praxis Precision Medicines (PRAX) After Its 1-Year Surge? [Yahoo! Finance]
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: Yahoo! Finance
The share price return sits at 2.9% over the past week, 4.5% over the past month, with a small year to date decline of 1.9%, while the 1 year return of 326.5% and 3 year return of 375.2% contrast with a 5 year decline of 66.5%. Recent interest in Praxis has been shaped by ongoing attention on its pipeline in neurological disorders and updates around its clinical programs, which tend to influence how investors think about future cash flows and risk. At the same time, sector wide focus on smaller biotech names has helped put stocks like Praxis under a brighter spotlight, adding to the share price swings you may have noticed. On our valuation checks, Praxis Precision Medicines scores 2 out of 6 on the valuation score . In this article, we look at how different valuation methods interpret that result and then finish with a framework that can help you make more sense of the valuation story. Praxis Precision Medicines scores just 2/6 on our valuation checks. See what other red flags
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus [Yahoo! Finance]Yahoo! Finance
- Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical StrategyGlobeNewswire
- Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Wedbush from $83.00 to $95.00. They now have an "underperform" rating on the stock.MarketBeat
- Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress [Yahoo! Finance]Yahoo! Finance
- Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of ProgressGlobeNewswire
PRAX
Earnings
- 11/5/25 - Beat
PRAX
Sec Filings
- 1/13/26 - Form 4
- 1/13/26 - Form 4
- 1/13/26 - Form 4
- PRAX's page on the SEC website